האיחוד האירופי - בולגרית - EMA (European Medicines Agency)

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - Стомашно-чревни стромални тумори - Антинеопластични средства - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

בולגריה - בולגרית - БАБХ (Българска агенция по безопасност на храните)

laboratorios maymó, s.a. - Парацетамол - разтвор за прилагане във водата за пиене - 400 mg/ml - прасета

האיחוד האירופי - בולגרית - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - доксорубицин хидрохлорид - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - Антинеопластични средства - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

האיחוד האירופי - בולגרית - EMA (European Medicines Agency)

sandoz gmbh - трастузумаб - breast neoplasms; stomach neoplasms - Антинеопластични средства - treatment of metastatic and early breast cancer and metastatic gastric cancer (mgc).